Dry Eye

The FDA and Palatin agreed on a clear regulatory path for PL9643 NDA submission in DED. The company hopes to start patient enrollment to start in the fourth quarter of calendar year 2024.

Understanding the latest innovative technologies.

Actionable tips to improve comfort and fit.

Jessilin Quint, OD, MBA, FAAO, and Selina McGee, OD, FAAO, weigh in on meibomian gland dysfunction and dry eye disease what to consider when choosing symptom management options.

The survey’s results were released by Bausch + Lomb last month and revealed that many participants did not know their symptoms were dry eye-related.

Adding a service to your practice can be scaled to your liking.

Results suggest higher exposures to lower temperatures and certain air pollutants could result in worsened ocular symptoms and increased tear osmolarity.

Vevizye was approved by the US FDA under the name Vevye in May 2023 for the treatment of moderate to severe dry eye disease.

The latest in market trends can offer insights into patient care.

The companies announced that they will be working to develop SGN’s micellar nanoparticle platform to be used with Eyenovia’s Optejet dispenser in a news release.

Increased pressure and inflammation require prompt treatment to avoid complications.

The collaboration agreement will allow the two companies to find a potential new treatment for chronic dry eye disease.

According to the company, the tuck-in acquisition will help expand its surgical presence in the United States and contribute to its leading position in dry eye.

Focusing on the care of patients with MGD, Jessilin Quint, OD, MBA, FAAO, and Selina McGee, OD, FAAO, provide key takeaways on treatment practices.

Dry eye experts provide comprehensive insights on the role of in-office procedural therapies.

Selina McGee, OD, FAAO, discusses the role of cyclosporine ophthalmic solution (VEVYE) in the treatment of dry eye disease.

Experts provide clinical insights on the first FDA-approved treatment for evaporative dry eye, perfluorohexyloctane ophthalmic solution (MEIBO).

Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO, discuss the first-line treatment of MGD, highlighting factors that inform treatment selection.

Experts on dry eye describe the potential long-term consequences for patients if MGD is left untreated.

The primary endpoint will be pain improvement as measured by visual analogue scale (VAS) compared to placebo.

The survey found that most participants may not know that their symptoms could be associated with eye dryness, including redness, fluctuating vision, a scratch, gritty, tired, or heavy feeling in the eye, or overall eye irritation.

Perfluorohexyloctane may slow evaporation to reduce dry eye.

Exploring strategies for effective management of a multifaceted condition.

The study also discovered a need for more blatant labeling on e-liquid containers to help reduce accidental contact with the ocular surface.

The company plans to finalize its Phase 3 development plans following an End-of-Phase 2 meeting with the FDA.